Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell therapy for cirrhosis: Five-Year safety watch

NCT ID NCT05093881

NEW Knowledge-focused Sponsor: Pharmicell Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are following 100 people with alcoholic liver cirrhosis who previously received Cellgram-LC, a stem cell therapy made from their own bone marrow. Over five years, the team checks by phone for serious side effects such as new cancers, immune reactions, or the need for a liver transplant. The study aims to learn whether the therapy causes any delayed safety problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cellgram-LC, a stem cell therapy made from the patient's own bone marrow
What this could lead to
If the therapy proves safe over five years, it could support further testing of stem cell treatments for alcoholic liver cirrhosis.
What could go wrong
This is an observational follow-up with no new treatment, so it cannot show whether the therapy works. It only tracks people who already received it, and any safety signals may take years to appear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 clinical trial and voluntarily consent to participate in this long-term follow-up study.

Ages

19 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants who received Cellgram-LC in the PMC-P-07 clinical trial. 2. Participants who voluntarily provide written informed consent to participate in this study. Exclusion Criteria: \- None.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcoholic liver cirrhosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcoholic liver cirrhosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcoholic liver cirrhosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Eunpyeong St. Mary's Hospital

    RECRUITING

    Seoul, South Korea

  • Gangnam Severance Hospital

    RECRUITING

    Seoul, South Korea

  • Gangneung Asan Hospital

    RECRUITING

    Gangneung-si, South Korea

  • Gangwon National University Hospital

    TERMINATED

    Chuncheon, South Korea

  • Hallym Univ. Medical Center

    RECRUITING

    Chuncheon, South Korea

  • Korea University Anam Hospital

    RECRUITING

    Seoul, South Korea

  • Korea University Ansan Hospital

    RECRUITING

    Ansan, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

  • Seoul St. Mary's Hospital

    RECRUITING

    Seoul, South Korea

  • Soonchunhyang University Hospital

    RECRUITING

    Bucheon-si, South Korea

  • Soonchunhyang University Hospital

    TERMINATED

    Cheonan, South Korea

  • Soonchunhyang University Hospital

    RECRUITING

    Seoul, South Korea

  • Wonju Severance Christian Hospital

    RECRUITING

    Wŏnju, South Korea

  • Yongin Severance Hospital

    RECRUITING

    Yongin, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.